CurveBeam AI Updates Share Purchase Plan Schedule to Align with General Meeting Results

CurveBeam AI’s Advanced Medical Imaging Solutions and Market Position

Operating within the specialised medical imaging technology sector, CurveBeam AI Limited designs and produces computed tomography (CT) scanners that incorporate artificial intelligence-driven clinical assessment platforms. The company’s flagship product, the HiRise™ scanner system, offers a unique capability in musculoskeletal imaging by performing weight-bearing CT scans. This innovation surpasses traditional CT and MRI imaging by capturing joint and bone anatomy under load, thereby enhancing diagnostic precision for clinicians managing musculoskeletal disorders.

CurveBeam AI’s business model integrates hardware manufacturing with a software-as-a-service (SaaS) platform, embedding AI-based clinical assessment tools within its imaging solutions. This comprehensive approach addresses diagnostic and management workflows for healthcare professionals treating musculoskeletal conditions. The dual-revenue streams from equipment sales and recurring software subscriptions strengthen the company’s customer relationships across hospitals and specialised imaging centres. CurveBeam AI’s operations span Australia, with its Melbourne headquarters, and the United States through its Pennsylvania facility.

Overview of the $5.0 Million Capital Raise and Placement Structure

Announced on 8 July 2026, CurveBeam AI’s capital raise consists of a $5.0 million placement alongside a Share Purchase Plan targeting eligible shareholders. The placement’s timetable remains unchanged, providing institutional and sophisticated investors with certainty. This dual-structure capital raise is standard in Australian equity markets, where placements cater to larger investors able to act swiftly, while SPPs offer retail shareholders proportional participation at comparable pricing.

The revision of the SPP timetable—without altering the placement schedule—reflects a strategic decision to improve shareholder engagement. Allowing shareholders to know the General Meeting results before committing funds via the SPP reduces uncertainty and supports informed participation. The $5.0 million raise underscores CurveBeam AI’s confidence in its growth prospects and the expanding market for weight-bearing CT imaging technology, with funds likely directed towards working capital, product development, market expansion, and operational scaling.

Updated Share Purchase Plan Timetable and Shareholder Participation

The revised SPP timetable outlines a clear subscription process for eligible shareholders. The eligibility record date is Tuesday, 7 July 2026 (7:00pm Sydney time), identifying shareholders entitled to participate. The SPP offer opens on Tuesday, 4 August 2026, with the Offer Booklet dispatched simultaneously. This schedule allows a four-week window for administrative preparation and shareholder notification.

The offer period extends until 5:00pm Sydney time on Friday, 28 August 2026, providing shareholders ample time to evaluate the offer and market conditions. Following the offer’s close, CurveBeam AI will announce results on Tuesday, 1 September 2026. Settlement of shares is scheduled for Thursday, 3 September 2026, with allotment occurring on Friday, 4 September 2026. This timeline aligns with standard Australian market practices, enabling prompt capital raise finalisation.

Strategic Reasons Behind the SPP Schedule Adjustment

Adjusting the SPP timetable to allow shareholders to consider the General Meeting outcome prior to participation demonstrates CurveBeam AI’s commitment to governance and stakeholder transparency. The General Meeting, expected to approve the placement and related capital structure changes, must conclude before retail shareholders finalize their investment decisions through the SPP. This sequencing ensures all shareholders have equal access to critical information before committing capital.

From an investor relations standpoint, this approach fosters confidence and informed decision-making among retail shareholders. Instead of requiring subscription based on a proposed General Meeting outcome, shareholders can vote with full context and then decide on SPP participation. The company’s announcement highlights that the revised timetable "allows eligible shareholders to consider the outcome of the General Meeting convened to approve the Placement before deciding whether to participate in the SPP," emphasizing the value placed on shareholder trust and transparency.

CurveBeam AI’s Global Operations and Workforce

CurveBeam AI operates across two continents with principal offices in Melbourne, Victoria, Australia, and Hatfield, Pennsylvania, USA. The Melbourne office, located at Level 10, 10 Queen Street, serves as the corporate headquarters and houses financial, administrative, investor relations, AI research and development, and intellectual property management functions under CFO and Company Secretary Phillip Auckland. This location anchors the company’s technical innovation within Australia’s technology sector.

The Global Operations Headquarters at 2800 Bronze Drive, Suite 110, Hatfield, Pennsylvania, manages manufacturing, supply chain, regulatory affairs, and North American commercial activities. This facility positions CurveBeam AI to effectively serve the US medical device market—the world’s largest healthcare market—while ensuring compliance with FDA and other regulatory bodies. Employing over 70 personnel across these sites, CurveBeam AI is a medium-sized medical device technology company with significant international reach, balancing Australian innovation with North American market penetration.

Product Innovation: Weight-Bearing CT Scanning and Clinical Benefits

The HiRise™ scanner is central to CurveBeam AI’s intellectual property and competitive differentiation. Unlike conventional CT and MRI scanners that image patients in non-weight-bearing positions, the HiRise™ system performs CT scans while patients stand under their own body weight. This weight-bearing imaging captures functional joint and bone conditions as they occur during daily activities, providing clinicians with more accurate diagnostic insights for conditions such as ankle instability, foot deformities, knee cartilage damage, and spinal alignment issues.

Integrated AI clinical assessment tools enhance the HiRise™ platform by analyzing imaging data to deliver structured clinical evaluations, workflow support, and decision-making aids. This SaaS-based software layer generates recurring revenue and strengthens customer loyalty, as clinicians rely on AI-driven insights for consistent diagnostics and treatment planning. The combined hardware and AI software platform establishes a robust competitive advantage in specialised medical imaging.

Capital Deployment and Growth Funding Strategy

Although specific allocations of the $5.0 million capital raise were not disclosed, typical uses for medical device companies like CurveBeam AI include expanding manufacturing capacity for the HiRise™ scanner to meet rising demand, pursuing regulatory approvals in additional markets such as the EU and Asia-Pacific, and investing in research and development to enhance hardware and AI software capabilities. Commercial expansion efforts, including sales force growth, market development, and customer education, also require significant funding. Additionally, working capital to support inventory and extended payment terms for hospital customers is a common capital use. The concurrent placement and SPP reflect management’s confidence in opportunities to deploy capital effectively to increase shareholder value and strengthen market position.

Market Landscape: Musculoskeletal Imaging and Diagnostic Innovation

CurveBeam AI operates in the growing musculoskeletal (MSK) diagnostic imaging market, driven by demographic trends such as aging populations and rising obesity, which increase joint-related pathologies. Traditional imaging modalities—radiography, CT, and MRI—are limited by their inability to capture weight-bearing anatomical conditions. Weight-bearing CT technology like the HiRise™ scanner addresses this gap by enabling clinicians to evaluate joint mechanics and structural alignment under physiological load, improving diagnostic accuracy.

The integration of AI into imaging workflows reflects a broader healthcare trend toward decision support systems that enhance diagnostic reliability and efficiency. Hospitals and specialty imaging centres focused on orthopedics, sports medicine, and podiatry increasingly adopt AI-augmented platforms for improved patient outcomes. CurveBeam AI’s comprehensive weight-bearing CT plus AI clinical assessment solution aligns with these trends, with the $5.0 million capital raise supporting anticipated market adoption and operational scaling.

Governance and Shareholder Approval Process

The revised SPP timetable depends on the General Meeting, which will seek shareholder approval for the placement and related capital transactions under the Corporations Act 2001 (Cth) and ASX Listing Rules. Australian regulations require shareholder consent for significant equity issuances, particularly when new shares exceed 15% of existing capital, ensuring democratic oversight and protecting shareholder interests.

By scheduling the General Meeting before the SPP offer period, CurveBeam AI ensures shareholders can vote with full knowledge of the capital raise structure and then participate in the SPP on equal terms. The company reserves the right to amend the timetable subject to regulatory or market developments, with all times referenced to Sydney, NSW time, providing a consistent temporal framework for stakeholders.

Risk Factors and Market Challenges

Investors should consider several risks associated with CurveBeam AI’s capital raise and commercial strategy. The medical device industry is heavily regulated, and delays or additional requirements in regulatory approvals could impact market expansion and capital needs. The competitive landscape includes large incumbents like Siemens, GE Healthcare, and Philips, which have greater resources and distribution capabilities and may develop competing weight-bearing CT technologies.

Adoption of the HiRise™ platform depends on clinical acceptance and reimbursement policies from healthcare payers; insufficient reimbursement rates could limit demand. Currency fluctuations affect earnings reported in Australian dollars, given the company’s US operations. Additionally, as a medium-sized firm with over 70 employees, key personnel departures could disrupt development or market execution. These factors should be weighed against CurveBeam AI’s strategic opportunity in advancing weight-bearing CT imaging technology.